
Stephanie M J Fliedner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/246669/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Landscape of the mitochondrial Hsp90 metabolome in tumours. Nature Communications, 2013, 4, 2139.	5.8	135
2	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clinical Chemistry, 2018, 64, 1646-1656.	1.5	121
3	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1122-1132.	1.8	120
4	Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. Journal of Molecular Medicine, 2015, 93, 93-104.	1.7	118
5	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2017, 177, 103-113.	1.9	82
6	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3295-3307.	1.8	34
7	Genotype and Tumor Locus Determine Expression Profile of Pseudohypoxic Pheochromocytomas and Paragangliomas. Neoplasia, 2013, 15, 435-IN22.	2.3	33
8	Warburg Effect's Manifestation in Aggressive Pheochromocytomas and Paragangliomas: Insights from a Mouse Cell Model Applied to Human Tumor Tissue. PLoS ONE, 2012, 7, e40949.	1.1	32
9	Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. Frontiers in Endocrinology, 2021, 12, 589451.	1.5	25
10	Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomas–Effect of Different Statins on Mouse Pheochromocytoma Cells. PLoS ONE, 2014, 9, e97712.	1.1	24
11	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	1.8	17
12	Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. Neoplasia, 2016, 18, 567-576.	2.3	16
13	Ganglioneuromas across age groups: Systematic review of individual patient data. Clinical Endocrinology, 2021, 94, 12-23.	1.2	16
14	Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. Cell and Tissue Research, 2010, 340, 607-612.	1.5	15
15	Pheochromocytoma and paraganglioma: genotype versus anatomic location as determinants of tumor phenotype. Cell and Tissue Research, 2018, 372, 347-365.	1.5	15
16	Cytocidal Activities of Topoisomerase 1 Inhibitors and 5-Azacytidine against Pheochromocytoma/Paraganglioma Cells in Primary Human Tumor Cultures and Mouse Cell Lines. PLoS ONE, 2014, 9, e87807.	1.1	14
17	Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells. American Journal of Cancer Research, 2015, 5, 1558-70.	1.4	10